Inactive Instrument

Highlights Acura Pharmaceuticals, Inc. OTC Bulletin Board

Equities

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

14/06	Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	CI
04/06	Acura Pharmaceuticals, Inc. and Acura Pharmaceutical Technologies, Inc Announce Executive Changes	CI

Highlights

Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC	26/03	CI
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets	01/23/01	CI
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03	31/23/31	CI
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement	16/23/16	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/23/30	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	30/23/30	CI
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC	28/23/28	CI
Acura Pharmaceuticals, Inc. Provides Development Update on LTX-03	13/23/13	CI
Acura Pharmaceuticals, Inc. Announces First Clinical Study for Its Investigational Drug LTX-03	03/23/03	CI
Acura Pharmaceuticals, Inc Enters into License, Development and Commercialization Agreement with Abuse Deterrent Pharmaceuticals LLC	15/22/15	CI
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03	01/22/01	CI
Acura Pharmaceuticals Provides Development Update on LTX-03	14/22/14	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
Earnings Flash (ACUR) ACURA PHARMACEUTICALS Posts Q3 Revenue $270,000	16/21/16	MT
Acura Pharmaceuticals, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2021	17/21/17	CI
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx LTX-03	27/21/27	CI
Acura Pharmaceuticals Provides Development Update on LTX-03	07/21/07	CI
Acura Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2021	18/21/18	CI
Acura Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2020	01/21/01	CI
Acura Pharmaceuticals : Earnings Flash (ACUR) ACURA PHARMACEUTICALS Reports Q3 Revenue $410,000	17/20/17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Acura Pharmaceuticals, Inc. OTC Bulletin Board

Equities

Highlights

Filters